NEXT-GENERATION NK CELL-BASED IMMUNOTHERAPIES FOR HARD-TO-TREAT CANCERS
Associate Professor Fernando S. F. Guimaraes, PhD, GAICD
Group Leader, Translational Innate Immunotherapy
Frazer Institute, Faculty of Medicine,
The University of Queensland, Australia
RESEARCHER PROFILE
Filmed in Brisbane, Australia | February 2025
Associate Professor Fernando Guimaraes is an internationally recognised leader in cancer immunotherapy and natural killer (NK) cell biology. Based at The University of Queensland, he leads innovative research focused on developing next-generation NK cell-based immunotherapies for hard-to-treat cancers, including sarcomas and neuroblastoma.
A/Prof Guimaraes completed his PhD at the Institut Pasteur and pursued postdoctoral research at QIMR Berghofer and WEHI before joining UQ in 2019. His pioneering work has significantly advanced understanding of immune evasion mechanisms in cancer, leading to potential breakthroughs in NK cell therapies. His research integrates systems biology, experimental oncology, and bioinformatics to design novel, targeted treatments resistant to tumour-induced immunosuppression. His contributions have earned him numerous awards, including the QLD Tall Poppy, UQ Frazer Institute Rising Star, Translational Research Institute – Connecting with the Clinic Awards.
He has published extensively in top-tier journals, secured and led major research funding (NHMRC, MRFF, US DoD) focused on NK cell therapies. A/Prof Guimaraes also plays a key role in mentoring early-career researchers, serving as the Chair of the Research Committee at Cure Cancer Australia and leading multiple international collaborations.
Source: supplied
https://orcid.org/0000-0002-2037-8946
-
Anne O’Neill
STATE GOVERNMENT SUPPORTING MEDICAL RESEARCH
@ NSW HEALTH, NEW SOUTH WALES AUSTRALIA -
Interventions for improving outcomes of children who are deaf or hard of hearing
Professor Teresa Ching is a Conjoint Professor at NextSense Institute and Macquarie University, and an Honorary Professor at the University of Queensland in Australia. Her current research focuses on devising culturally sensitive practices in early detection and intervention to maximise children’s outcomes. Working with international colleagues, her current research is also directed towards developing global guidelines and recommendations for hearing screening beyond the newborn period, so that all children can benefit from early detection and intervention. The ultimate goal is to attain equity of care and outcomes for all children with hearing difficulties.
-
Radiation therapy techniques and combination treatments for sarcoma
Professor Angela Hong MBBS, MMed, PhD, FRANZCR is a Professor at Sydney Medical School of the University of Sydney. She is a radiation oncologist and has been a member of the Multidisciplinary Bone and Soft Tissue Tumour Clinic at Royal Prince Alfred Hospital/Chris O’Brien Lifehouse for the past 15 years.
As a radiation oncologist located in Sydney, Australia, Professor Hong is focused on treating patients with bone and soft tissue sarcoma. And as a clinician scientist, her research focuses on developing innovative radiation therapy technique and combination treatments to improve the outcome for patients with sarcoma.
